{
    "nctId": "NCT01155453",
    "briefTitle": "A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients",
    "officialTitle": "A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced and Selected Solid Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 113,
    "primaryOutcomeMeasure": "Maximum Tolerated Dose (MTD) and/or recommended phase II dose (RP2D) and schedule of BKM120+GSK1120212",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* histologically/ cytologically confirmed, advanced non resectable solid tumors\n* Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0\n\nExclusion Criteria:\n\n* Patients with primary Central Nervous System (CNS) tumor or CNS tumor involvement.\n* Clinically manifested diabetes mellitus - Unacceptable ocular/retinal conditions\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}